Novo Nordisk holds 72% international and 50%+ U.S. market share in GLP-1 treatments, serving 46 million patients globally.

Higher protein intake may be protective against muscle loss, which is tied to less improvement in glucose homeostasis.

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...

A new report from The Center for Medicine in the Public Interest (CMPI) warns that regulators are failing to stop the illegal ...

In recent times, medications like Ozempic (semaglutide) have gained popularity not only for managing type 2 diabetes but also ...

A new study from Mass Eye and Ear suggests that people taking semaglutide, a drug sold as Ozempic and Wegovy, may have a ...

We can't have it both ways. If we want more cutting-edge drugs, we have to protect the property rights that make them ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

Patients put on weight loss drugs like Ozempic and Wegovy may start regaining weight within weeks of discontinuing them, a ...

Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after halting their prescription, ...

Eight weeks. That’s how long it takes, on average, for the pounds to begin creeping back after someone stops taking the world ...